MX370348B - Miembros de la familia il-1 modificados dirigidos. - Google Patents
Miembros de la familia il-1 modificados dirigidos.Info
- Publication number
- MX370348B MX370348B MX2016000723A MX2016000723A MX370348B MX 370348 B MX370348 B MX 370348B MX 2016000723 A MX2016000723 A MX 2016000723A MX 2016000723 A MX2016000723 A MX 2016000723A MX 370348 B MX370348 B MX 370348B
- Authority
- MX
- Mexico
- Prior art keywords
- family member
- cytokine
- modified
- mutant
- family members
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 abstract 5
- 108090000695 Cytokines Proteins 0.000 abstract 5
- 102000000589 Interleukin-1 Human genes 0.000 abstract 4
- 108010002352 Interleukin-1 Proteins 0.000 abstract 4
- 102000039996 IL-1 family Human genes 0.000 abstract 3
- 108091069196 IL-1 family Proteins 0.000 abstract 3
- 230000008685 targeting Effects 0.000 abstract 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 abstract 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 abstract 1
- 102000003675 cytokine receptors Human genes 0.000 abstract 1
- 108010057085 cytokine receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306047 | 2013-07-19 | ||
| PCT/EP2014/064283 WO2015007542A1 (en) | 2013-07-19 | 2014-07-04 | Targeted modified il-1 family members |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016000723A MX2016000723A (es) | 2016-12-20 |
| MX370348B true MX370348B (es) | 2019-12-10 |
Family
ID=48874235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000723A MX370348B (es) | 2013-07-19 | 2014-07-04 | Miembros de la familia il-1 modificados dirigidos. |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9932409B2 (enExample) |
| EP (1) | EP3022226B1 (enExample) |
| JP (1) | JP6475713B2 (enExample) |
| KR (1) | KR102275090B1 (enExample) |
| CN (1) | CN105612180B (enExample) |
| AU (1) | AU2014292377B2 (enExample) |
| BR (1) | BR112016001128A2 (enExample) |
| CA (1) | CA2918518C (enExample) |
| DK (1) | DK3022226T3 (enExample) |
| ES (1) | ES2714504T3 (enExample) |
| IL (1) | IL243466B (enExample) |
| MX (1) | MX370348B (enExample) |
| SG (1) | SG11201600167SA (enExample) |
| WO (1) | WO2015007542A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002674A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| MX2018005348A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para transduccion de tumores. |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| EP3454887B1 (en) | 2016-05-13 | 2021-01-20 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| CN110114368B (zh) | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| JP7660343B2 (ja) * | 2017-03-03 | 2025-04-11 | オブシディアン セラピューティクス， インコーポレイテッド | 免疫療法のための組成物及び方法 |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| CN119285770A (zh) | 2017-08-09 | 2025-01-10 | 奥里尼斯生物科学有限公司 | Pd-1和pd-l1结合剂 |
| JP7347899B2 (ja) | 2017-08-09 | 2023-09-20 | オリオンズ バイオサイエンス インコーポレイテッド | Ｃｄ８結合物質 |
| CN117924493A (zh) | 2017-08-09 | 2024-04-26 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| EP3733716A4 (en) * | 2017-12-26 | 2021-11-24 | Nanjing GenScript Biotech Co., Ltd. | DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE |
| WO2019148089A1 (en) | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| MX2020008208A (es) | 2018-02-05 | 2020-11-09 | Orionis Biosciences Inc | Agentes de unión a fibroblastos y uso de estos. |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| US20230293652A1 (en) * | 2020-07-07 | 2023-09-21 | Orionis Biosciences, Inc. | Immunostimulatory adjuvants |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU632372B2 (en) | 1989-08-22 | 1992-12-24 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) * | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| WO2001029870A1 (en) * | 1999-10-21 | 2001-04-26 | Sarnoff Corporation | Bi-potential electrode space-saving cathode ray tube |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| JP2010531666A (ja) * | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
| KR101661770B1 (ko) | 2007-09-21 | 2016-10-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함 |
| US8334101B2 (en) * | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| JP2012510806A (ja) | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | 単鎖逆平行コイルドコイルタンパク質 |
| PE20120630A1 (es) * | 2009-08-17 | 2012-05-26 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| US20130115189A1 (en) * | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| WO2012170072A1 (en) | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| US9492562B2 (en) | 2012-01-20 | 2016-11-15 | Vib Vzw | Targeted human-interferon fusion proteins |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
-
2014
- 2014-07-04 MX MX2016000723A patent/MX370348B/es active IP Right Grant
- 2014-07-04 DK DK14735574.7T patent/DK3022226T3/en active
- 2014-07-04 ES ES14735574T patent/ES2714504T3/es active Active
- 2014-07-04 SG SG11201600167SA patent/SG11201600167SA/en unknown
- 2014-07-04 CN CN201480040652.6A patent/CN105612180B/zh active Active
- 2014-07-04 EP EP14735574.7A patent/EP3022226B1/en active Active
- 2014-07-04 CA CA2918518A patent/CA2918518C/en active Active
- 2014-07-04 US US14/905,352 patent/US9932409B2/en active Active
- 2014-07-04 JP JP2016526518A patent/JP6475713B2/ja active Active
- 2014-07-04 KR KR1020167002679A patent/KR102275090B1/ko active Active
- 2014-07-04 BR BR112016001128-7A patent/BR112016001128A2/pt not_active Application Discontinuation
- 2014-07-04 AU AU2014292377A patent/AU2014292377B2/en active Active
- 2014-07-04 WO PCT/EP2014/064283 patent/WO2015007542A1/en not_active Ceased
-
2016
- 2016-01-05 IL IL24346616A patent/IL243466B/en active IP Right Grant
-
2018
- 2018-02-21 US US15/901,545 patent/US20180186894A1/en not_active Abandoned
-
2019
- 2019-03-21 US US16/360,793 patent/US20190202934A1/en not_active Abandoned
-
2020
- 2020-04-28 US US16/860,660 patent/US20200255545A1/en not_active Abandoned
-
2023
- 2023-02-01 US US18/163,026 patent/US20230235086A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230235086A1 (en) | 2023-07-27 |
| US9932409B2 (en) | 2018-04-03 |
| AU2014292377B2 (en) | 2019-08-01 |
| WO2015007542A1 (en) | 2015-01-22 |
| DK3022226T3 (en) | 2019-03-25 |
| CA2918518C (en) | 2022-08-16 |
| EP3022226A1 (en) | 2016-05-25 |
| CN105612180A (zh) | 2016-05-25 |
| CN105612180B (zh) | 2019-11-12 |
| KR20160108293A (ko) | 2016-09-19 |
| BR112016001128A2 (pt) | 2018-01-23 |
| EP3022226B1 (en) | 2018-12-05 |
| US20180186894A1 (en) | 2018-07-05 |
| US20200255545A1 (en) | 2020-08-13 |
| IL243466B (en) | 2019-11-28 |
| JP2016527221A (ja) | 2016-09-08 |
| ES2714504T3 (es) | 2019-05-28 |
| IL243466A0 (en) | 2016-03-31 |
| JP6475713B2 (ja) | 2019-02-27 |
| CA2918518A1 (en) | 2015-01-22 |
| SG11201600167SA (en) | 2016-02-26 |
| AU2014292377A1 (en) | 2016-02-04 |
| US20160152730A1 (en) | 2016-06-02 |
| US20190202934A1 (en) | 2019-07-04 |
| KR102275090B1 (ko) | 2021-07-09 |
| MX2016000723A (es) | 2016-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX370348B (es) | Miembros de la familia il-1 modificados dirigidos. | |
| MX370565B (es) | Miembros de la familia tnf modificados dirigidos. | |
| AU2013211059A8 (en) | Targeted mutant alpha-helical bundle cytokines | |
| PH12012502215A1 (en) | Anti-fgfr2 antibodies | |
| MX377712B (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| MX2016002719A (es) | Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias. | |
| EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
| PH12016500781A1 (en) | Novel anti-claudin antibodies and methods of use | |
| CR20130668A (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| PH12016501109A1 (en) | Novel anti-dpep3 antibodies and methods of use | |
| BR112015023557A2 (pt) | proteínas de ligações dual específicas direcionadas contra tnfa | |
| WO2012175222A8 (en) | AN IL-15 AND IL-15Rα SUSHI DOMAIN BASED IMMUNOCYTOKINES | |
| MX375441B (es) | Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. | |
| MY167920A (en) | HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF | |
| MX2016010128A (es) | Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo. | |
| MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
| EP4219552A3 (en) | Il-11r binding proteins and uses thereof | |
| MX2015006859A (es) | Anticuerpos anti-vegf y sus usos. | |
| EA201390669A1 (ru) | Способы и композиции для иммунотерапии заболеваний нервной системы | |
| EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
| EA201690992A1 (ru) | Антитела, специфичные к fcrn | |
| BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer | |
| MX368474B (es) | Uso de benralizumab para mejorar síntomas de asma. | |
| WO2012138880A9 (en) | Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2) | |
| MX2019006676A (es) | Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: NOVOZYMES A/S |
|
| FG | Grant or registration |